Julia M. Migliorati

MSc. Student (2021-2023)

Department of Pharmaceutical Sciences

Education

2016-2020
BSc. in Biology
University of Hartford
2020-2021
Pharm.D. Student
University of Connecticut School of Pharmacy
2021-2023
MSc. Student in Pharmacology
University of Connecticut School of Pharmacy

 

Working Experience

2019
Undergraduate Research, University of Hartford
2019
Summer Internship, Rx Health Pharmacy in Rocky Hill, CT

 

Honors and Awards

2018
Dean’s list, University of Hartford
2019
Dean’s list, University of Hartford
2020
Dean’s list, University of Hartford
2022
National Fellowships Incentive Program Award, The Office of National Scholarships and Fellowships of University of Connecticut
2022
Conference Participation Award, The Graduate School of University of Connecticut

 

Extracurricular Activities

2016-2020
Women’s golf, University of Hartford
2018-2019
Junior Achievement Student Teaching, Golf camps of University of Connecticut

 

Poster Presentations

04/2022
Experimental Biology Meeting, Philadelphia, PA
Migliorati JM, Liu A, Liu S, Gogate A, Nair S, Bahal R, Rasmussen TP, Manautou JE, and Zhong XB Absorption, distribution, metabolism, and excretion of the FDA-approved antisense oligo nucleotide drugs
09/2022
ISSX/MDO 2022 Meeting, Seattle, WA
Migliorati JM, Tawfik SM, and Zhong XB. A direct systematic comparision of therapeutic efficacy of antisense oligonucleotide and small interfering RNA drugs in in vitro models
09/2022
ISSX/MDO 2022 Meeting, Seattle, WA
Tawfik SM, Migliorati JM, and Zhong XB. A mega-analysis on ADME and toxicity of inotersen, patisiran, and vutrisiran for the treatment of hereditary transthyretin-mediated amyloidosis

 

Publications

Migliorati JM and Zhong XB. Mutations in muscle-type creatine kinase impact HIV prevention. Trends in Pharmacological Sciences, 2022, 43(3):165-167. PMID:34887127. DOI:10.1016/j.tips.2021.11.017.

Migliorati JM, Jin J, and Zhong XB. Drug of the Month: siRNA drug Leqvio (inclisiran) to lower cholesterol. Trends in Pharmacological Sciences, 2022, 43(5):455-456. PMID:35307191. DOI:10.1016/j.tips.2022.02.003.

Migliorati J, Liu S, Liu A, Gogate A, Nair S, Bahal R, Rasmussen TP, Manautou JE, and Zhong XB. Absorption, distribution, metabolism, and excretion of US Food and Drug Administration-approved antisense oligo nucleotide drugs. Drug Metabolism and Disposition, 2022, 50(6):888-897. PMID:35221287. DOI:10.1124/dmd.121.000417.

Liu A, Zhao J, Shah M, Migliorati JM, Tawfik SM, Bahal R, Rasmussen TP, Manautou JE, and Zhong XB. Nedosiran, a candidate siRNA drug for the treatment of primary hyperoxaluria: design, development, and clinical studies. ACS Pharmacol Transl Sci, 2022. DOI:10.1021/acsptsci.2c00110.

 

Contact Information
Emailjulia.migliorati@uconn.edu
Phone860-486-6803
Mailing AddressDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, 69 North Eagleville Road, Storrs, CT 06269
Office LocationPBB-230A